Melinta reports Phase III success for antibiotic
This article was originally published in Scrip
Executive Summary
Connecticut-based Melinta Therapeutics says that a Phase III study of its lead product, the investigational fluoroquinalone antibiotic, delafloxacin IV has met its primary end point.